|
G |
5031439G07Rik |
RIKEN cDNA 5031439G07 gene |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KIAA0930 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:84,828,137...84,872,503
Ensembl chr15:84,828,137...84,872,752
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA] Cycloheximide results in increased expression of ABCB1 mRNA Cycloheximide inhibits the reaction [[Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [[Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; Cycloheximide inhibits the reaction [tetrabromobisphenol A results in increased expression of and results in increased activity of ABCB1A protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] |
CTD |
PMID:7476894 PMID:18474546 PMID:30830211 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:11331069 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of ABCC3 mRNA Cycloheximide results in increased expression of ABCC3 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc5 |
ATP-binding cassette, sub-family C member 5 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of ABCC5 mRNA Cycloheximide results in decreased expression of ABCC5 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ACSL3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:78,635,600...78,685,462
Ensembl chr 1:78,635,542...78,685,460
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of ACSL6 mRNA] |
CTD |
PMID:10585473 |
|
NCBI chr11:54,194,580...54,255,582
Ensembl chr11:54,194,624...54,255,582
|
|
G |
Adam17 |
a disintegrin and metallopeptidase domain 17 |
multiple interactions decreases stability |
ISO |
cordycepin inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]; N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein] |
CTD |
PMID:36558177 |
|
NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of ADAM9 protein] |
CTD |
PMID:17018608 |
|
NCBI chr 8:25,439,627...25,507,138
Ensembl chr 8:25,439,627...25,506,943
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of ADM mRNA] Cycloheximide results in increased expression of ADM mRNA |
CTD |
PMID:11032871 |
|
NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
|
|
G |
Adora2b |
adenosine A2b receptor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ADORA2B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:62,139,810...62,157,278
Ensembl chr11:62,139,810...62,157,279
|
|
G |
Adrb2 |
adrenergic receptor, beta 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of ADRB2 mRNA; Cycloheximide results in increased expression of ADRB2 protein [Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA; Cycloheximide inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; N(6)-benzoyl-cyclic AMP promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA] |
CTD |
PMID:22483689 PMID:24705868 |
|
NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030
|
|
G |
Ago3 |
argonaute RISC catalytic subunit 3 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 4:126,220,797...126,323,360
Ensembl chr 4:126,225,497...126,323,349
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions decreases expression increases localization |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein] Cycloheximide results in increased localization of AHR protein [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Tretinoin co-treated with Cycloheximide] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein] |
CTD |
PMID:9145908 PMID:10777561 PMID:12002481 PMID:12147270 PMID:15385644 PMID:16226227 PMID:20570689 PMID:21807577 More...
|
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akap5 |
A kinase anchor protein 5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP5 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:76,371,652...76,380,925
Ensembl chr12:76,371,665...76,380,927
|
|
G |
Akap6 |
A kinase anchor protein 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP6 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:52,745,371...53,202,351
Ensembl chr12:52,746,166...53,202,382
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein] |
CTD |
PMID:21787718 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases phosphorylation |
ISO |
Cycloheximide inhibits the reaction [[Hydrogen Peroxide co-treated with sodium arsenite] results in increased phosphorylation of AKT1 protein] Cycloheximide results in increased phosphorylation of AKT1 protein |
CTD |
PMID:12472888 PMID:28634229 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase family 1, subfamily A3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:66,040,640...66,077,225
Ensembl chr 7:66,040,638...66,077,265
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase family 3, subfamily A1 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of ALDH3A1 mRNA] |
CTD |
PMID:1953764 |
|
NCBI chr11:61,099,336...61,109,244
Ensembl chr11:61,098,363...61,109,247
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase family 3, subfamily A2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ALOX5AP mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:149,201,814...149,224,963
Ensembl chr 5:149,201,577...149,224,963
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
decreases activity multiple interactions |
ISO |
Cycloheximide results in decreased activity of ALPI protein Cycloheximide inhibits the reaction [Fish Oils results in increased activity of ALPI protein] |
CTD |
PMID:15599000 PMID:20362602 |
|
NCBI chr 1:87,025,724...87,029,328
Ensembl chr 1:87,025,724...87,029,328
|
|
G |
Amhr2 |
anti-Mullerian hormone type 2 receptor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AMHR2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr15:102,353,437...102,363,075
Ensembl chr15:102,353,802...102,363,068
|
|
G |
Ank2 |
ankyrin 2, brain |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ANK2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:126,715,256...127,293,996
Ensembl chr 3:126,715,261...127,292,999
|
|
G |
Ankrd27 |
ankyrin repeat domain 27 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ANKRD27 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:35,285,652...35,338,662
Ensembl chr 7:35,285,669...35,338,651
|
|
G |
Aoc1 |
amine oxidase, copper-containing 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased activity of AOC1 protein] |
CTD |
PMID:2860926 PMID:6218830 |
|
NCBI chr 6:48,872,189...48,886,122
Ensembl chr 6:48,849,830...48,886,122
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of APAF1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of APAF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of AQP1 mRNA] |
CTD |
PMID:22415096 |
|
NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
ISO |
[Lactic Acid co-treated with Cycloheximide] results in increased expression of AQP4 protein |
CTD |
PMID:18406487 |
|
NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039
|
|
G |
Areg |
amphiregulin |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of AREG mRNA Cycloheximide results in increased expression of AREG mRNA |
CTD |
PMID:15072547 PMID:15228094 |
|
NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291
|
|
G |
Armc5 |
armadillo repeat containing 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ARMC5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:127,836,460...127,844,272
Ensembl chr 7:127,836,514...127,844,272
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
EXP |
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein] |
CTD |
PMID:12002481 PMID:20570689 |
|
NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ASB1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:91,467,725...91,487,312
Ensembl chr 1:91,468,266...91,487,311
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein] |
CTD |
PMID:23593480 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein] Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein] |
CTD |
PMID:18533110 PMID:23593480 PMID:24057571 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atg13 |
autophagy related 13 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of ATG13 protein |
CTD |
PMID:27629431 |
|
NCBI chr 2:91,504,957...91,540,947
Ensembl chr 2:91,504,963...91,540,921
|
|
G |
Atp7a |
ATPase, Cu++ transporting, alpha polypeptide |
multiple interactions decreases expression |
ISO |
cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein] |
CTD |
PMID:23174565 |
|
NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AVPR1A mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:122,284,404...122,289,358
Ensembl chr10:122,284,404...122,289,357
|
|
G |
Bach1 |
BTB and CNC homology 1, basic leucine zipper transcription factor 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of BACH1 protein tetrachlorobenzoquinone promotes the reaction [Cycloheximide results in decreased expression of BACH1 protein] |
CTD |
PMID:27393035 |
|
NCBI chr16:87,495,842...87,530,234
Ensembl chr16:87,495,833...87,530,234
|
|
G |
Bap1 |
Brca1 associated protein 1 |
multiple interactions |
EXP |
BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein] |
CTD |
PMID:37414201 |
|
NCBI chr14:30,973,358...30,981,887
Ensembl chr14:30,973,407...30,981,901
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein] |
CTD |
PMID:9790906 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BBOX1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] |
CTD |
PMID:11726273 PMID:22343715 PMID:34303041 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of BCL2L1 protein alternative form Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein] |
CTD |
PMID:9326359 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl2l14 |
BCL2 like 14 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of BCL2L14 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:134,373,292...134,415,687
Ensembl chr 6:134,373,281...134,415,699
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase, type 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BDH1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:31,241,115...31,277,719
Ensembl chr16:31,241,098...31,277,719
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of BECN1 protein] |
CTD |
PMID:16882451 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of BGLAP mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of BGLAP mRNA] |
CTD |
PMID:17203194 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; Cycloheximide inhibits the reaction [vorinostat results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein] |
CTD |
PMID:11535817 PMID:12925536 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein] |
CTD |
PMID:19442826 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Brca1 |
breast cancer 1, early onset |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA] BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]; Cycloheximide inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA] |
CTD |
PMID:10344722 PMID:29576526 PMID:37414201 |
|
NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781
|
|
G |
Brca2 |
breast cancer 2, early onset |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA] |
CTD |
PMID:10344722 |
|
NCBI chr 5:150,445,759...150,493,612
Ensembl chr 5:150,446,095...150,493,794
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CALB1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:15,881,264...15,906,709
Ensembl chr 4:15,881,264...15,908,064
|
|
G |
Caml |
calcium modulating ligand |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CAMLG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:55,770,818...55,780,229
Ensembl chr13:55,770,818...55,780,224
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CASP1 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of CASP1 protein modified form]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP1 mRNA] |
CTD |
PMID:11007951 PMID:26901245 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein] obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]] |
CTD |
PMID:12760867 PMID:12925536 PMID:14502240 PMID:15537749 PMID:15685448 PMID:15860571 PMID:17295206 PMID:18222423 PMID:18636177 PMID:22343715 PMID:34303041 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:5,308,816...5,336,791
Ensembl chr 9:5,308,828...5,336,783
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of CASP7 mRNA]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein] |
CTD |
PMID:12760867 PMID:16166294 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein] Cycloheximide results in increased activity of CASP8 protein |
CTD |
PMID:12760867 PMID:12925536 PMID:15924153 PMID:18222423 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO EXP |
[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein] Cycloheximide results in increased activity of CASP9 protein |
CTD |
PMID:12925536 PMID:14502240 PMID:18222423 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of CAT protein]; Cycloheximide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CAT protein] |
CTD |
PMID:6845354 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Catsper4 |
cation channel, sperm associated 4 |
affects response to substance |
ISO |
CATSPER4 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 4:133,939,276...133,954,743
Ensembl chr 4:133,939,281...133,954,694
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of CAV1 mRNA] |
CTD |
PMID:15314095 |
|
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Cbx1 |
chromobox 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CBX1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:96,679,506...96,699,808
Ensembl chr11:96,679,953...96,699,466
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]] |
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CCL5 mRNA Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]] |
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Acetylcysteine results in increased expression of CCN1 protein] |
CTD |
PMID:21055460 |
|
NCBI chr 3:145,352,726...145,355,740
Ensembl chr 3:145,352,731...145,355,736
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CCN2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccn3 |
cellular communication network factor 3 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of CCN3 mRNA Cycloheximide results in increased expression of CCN3 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr15:54,609,306...54,617,158
Ensembl chr15:54,609,098...54,617,435
|
|
G |
Ccn4 |
cellular communication network factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased expression of CCN4 mRNA] |
CTD |
PMID:19238344 |
|
NCBI chr15:66,763,337...66,795,050
Ensembl chr15:66,763,169...66,795,050
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of CCNA2 mRNA Cycloheximide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[gingerol co-treated with Cycloheximide] results in increased degradation of CCND1 protein; Cycloheximide inhibits the reaction [CXCL8 protein results in increased expression of CCND1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]] |
CTD |
PMID:17606477 PMID:18058799 PMID:25923732 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd3 |
cyclin D3 |
affects expression multiple interactions |
EXP |
Cycloheximide affects the expression of CCND3 mRNA Cycloheximide affects the reaction [Estradiol affects the expression of CCND3 mRNA] |
CTD |
PMID:9094091 |
|
NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCT5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:31,590,946...31,601,992
Ensembl chr15:31,590,946...31,601,950
|
|
G |
Cd38 |
CD38 antigen |
multiple interactions |
ISO |
Cycloheximide affects the reaction [Tretinoin results in increased expression of CD38 mRNA] |
CTD |
PMID:21393419 |
|
NCBI chr 5:44,026,153...44,069,714
Ensembl chr 5:44,025,895...44,069,717
|
|
G |
Cd3e |
CD3 antigen, epsilon polypeptide |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD3E mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:44,910,033...44,920,961
Ensembl chr 9:44,910,038...44,920,925
|
|
G |
Cd44 |
CD44 antigen |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of CD44 protein] |
CTD |
PMID:9929743 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cd47 |
CD47 antigen (Rh-related antigen, integrin-associated signal transducer) |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD47 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:49,671,691...49,732,799
Ensembl chr16:49,620,896...49,735,373
|
|
G |
Cd63 |
CD63 antigen |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD63 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:128,731,577...128,748,691
Ensembl chr10:128,736,858...128,748,691
|
|
G |
Cd8a |
CD8 subunit alpha |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CD8A mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:71,350,411...71,356,155
Ensembl chr 6:71,350,411...71,356,157
|
|
G |
Cdc42se2 |
CDC42 small effector 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CDC42SE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CDC42SE2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:54,608,241...54,678,549
Ensembl chr11:54,608,282...54,678,501
|
|
G |
Cdca5 |
cell division cycle associated 5 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CDCA5 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CDCA5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr19:6,135,127...6,141,803
Ensembl chr19:6,135,013...6,141,807
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of CDCA7L protein] |
CTD |
PMID:31285264 |
|
NCBI chr12:117,807,209...117,842,441
Ensembl chr12:117,768,024...117,842,441
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA] |
CTD |
PMID:12800980 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of CDKN1A mRNA]; Cycloheximide inhibits the reaction [Troglitazone results in increased expression of CDKN1A protein]; Furazolidone promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein] Cycloheximide results in decreased expression of CDKN1A mRNA; Cycloheximide results in decreased expression of CDKN1A protein Cycloheximide inhibits the reaction [manganese chloride results in increased expression of CDKN1A protein] Cycloheximide promotes the reaction [Dexamethasone results in decreased expression of CDKN1A protein]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CDKN1A mRNA] |
CTD |
PMID:10441511 PMID:12690110 PMID:22542671 PMID:24211769 PMID:26687534 PMID:28424418 PMID:28940008 PMID:31645432 More...
|
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
increases expression |
ISO |
Cycloheximide results in increased expression of CDKN2A mRNA |
CTD |
PMID:17257637 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of CFLAR protein; Cycloheximide results in decreased expression of CFLAR protein alternative form; Cycloheximide results in decreased expression of CFLAR protein modified form shogaol promotes the reaction [Cycloheximide results in decreased expression of CFLAR protein modified form] |
CTD |
PMID:12663669 PMID:15924153 PMID:16077199 PMID:16951203 PMID:25619640 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
affects expression |
ISO |
Cycloheximide affects the expression of CFTR mRNA |
CTD |
PMID:17290305 |
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1, CNS |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dihydrotestosterone results in decreased expression of CHRM1 mRNA] |
CTD |
PMID:17624924 |
|
NCBI chr19:8,641,369...8,660,970
Ensembl chr19:8,641,153...8,660,951
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
EXP |
Cycloheximide results in increased expression of CISH mRNA |
CTD |
PMID:23237828 |
|
NCBI chr 9:107,173,858...107,179,983
Ensembl chr 9:107,173,225...107,179,983
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CITED2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:17,598,452...17,601,422
Ensembl chr10:17,598,966...17,601,422
|
|
G |
Ckb |
creatine kinase, brain |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Estradiol results in increased expression of CKB protein]; Cycloheximide inhibits the reaction [Methoxychlor results in increased expression of CKB protein] |
CTD |
PMID:7839363 |
|
NCBI chr12:111,635,789...111,638,772
Ensembl chr12:111,635,795...111,638,772
|
|
G |
Clcn3 |
chloride channel, voltage-sensitive 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CLCN3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:61,363,423...61,436,351
Ensembl chr 8:61,363,423...61,436,334
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]] Cycloheximide results in decreased expression of and affects the localization of CNR1 protein |
CTD |
PMID:17041005 PMID:22258905 PMID:27513693 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Col10a1 |
collagen, type X, alpha 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16350840 |
|
NCBI chr10:34,265,977...34,273,081
Ensembl chr10:34,265,977...34,273,081
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA] |
CTD |
PMID:15962303 PMID:17203194 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crppa |
CDP-L-ribitol pyrophosphorylase A |
affects response to substance |
ISO |
CRPPA gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr12:36,430,334...36,739,502
Ensembl chr12:36,431,449...36,739,502
|
|
G |
Cryl1 |
crystallin, lambda 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CRYL1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr14:57,512,491...57,635,940
Ensembl chr14:57,512,450...57,635,986
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc results in increased expression of CSF1 mRNA] |
CTD |
PMID:12112025 PMID:17295206 PMID:18636177 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein] |
CTD |
PMID:9606035 PMID:10645887 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Csnk1d |
casein kinase 1, delta |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:120,848,535...120,882,180
Ensembl chr11:120,849,816...120,882,156
|
|
G |
Csnk2b |
casein kinase 2, beta polypeptide |
decreases degradation multiple interactions |
EXP |
Cycloheximide results in decreased degradation of CSNK2B protein Diethylhexyl Phthalate inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]; TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein] |
CTD |
PMID:37302538 |
|
NCBI chr17:35,335,171...35,341,029
Ensembl chr17:35,335,172...35,341,029
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
EXP |
Cycloheximide results in decreased expression of CTNNB1 protein Phenobarbital affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein] |
CTD |
PMID:27693619 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Azithromycin results in increased activity of CTSB protein] |
CTD |
PMID:8830663 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr18:3,382,970...3,436,700
Ensembl chr18:3,382,988...3,436,377
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]] |
CTD |
PMID:22121136 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CXCL8 mRNA [TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein; Cycloheximide inhibits the reaction [cadmium sulfate results in increased secretion of CXCL8 protein]; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL1B protein]; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL6 protein]; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of TNF protein]; Cycloheximide inhibits the reaction [CXCL8 protein results in increased expression of CCND1 protein]; Cycloheximide inhibits the reaction [deoxynivalenol results in increased expression of CXCL8 protein]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [Zinc deficiency results in decreased expression of CXCL8 protein]]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL8 protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]] |
CTD |
PMID:8071060 PMID:12812920 PMID:17606477 PMID:18308354 PMID:21146893 PMID:22094458 PMID:24068670 More...
|
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CYCS mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of CYP11A1 protein |
CTD |
PMID:21126571 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity decreases expression |
ISO |
Cycloheximide results in decreased activity of CYP19A1 protein Cycloheximide results in decreased expression of CYP19A1 protein |
CTD |
PMID:16480277 PMID:21126571 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects expression increases expression multiple interactions |
ISO EXP |
Cycloheximide affects the expression of CYP1A1 mRNA Cycloheximide results in increased expression of CYP1A1 mRNA 3'-methoxy-4'-nitroflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; [Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; beta-Naphthoflavone promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide promotes the reaction [[Benzo(a)pyrene co-treated with Calcitriol] results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Skatole results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Piperonyl Butoxide co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dactinomycin promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1321828 PMID:1849469 PMID:1934297 PMID:2985607 PMID:8647108 PMID:9102211 PMID:9145908 PMID:9233375 PMID:10777561 PMID:11007951 PMID:11516172 PMID:11710520 PMID:12002481 PMID:12111005 PMID:15371557 PMID:15385644 PMID:16093525 PMID:17599377 PMID:17606337 PMID:19244278 PMID:19684285 PMID:20187624 PMID:20570689 PMID:22037238 PMID:28424418 PMID:29524502 More...
|
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:1849469 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1B1 mRNA; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]] Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of CYP1B1 protein] |
CTD |
PMID:9145908 PMID:19684285 PMID:21867498 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
alpha-naphthoflavone inhibits the reaction [Cycloheximide promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]]; Cycloheximide inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:19244278 |
|
NCBI chr 2:170,324,877...170,339,065
Ensembl chr 2:170,324,628...170,339,065
|
|
G |
Cyp2a5 |
cytochrome P450, family 2, subfamily a, polypeptide 5 |
increases expression multiple interactions decreases expression |
EXP ISO |
Cycloheximide results in increased expression of CYP2A5 mRNA Bilirubin inhibits the reaction [Cycloheximide results in decreased expression of CYP2A6 protein] |
CTD |
PMID:9007836 PMID:22465937 |
|
NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases degradation |
ISO |
(4-amidinophenyl)methanesulfonyl fluoride inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; acetonitrile inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Carbon Tetrachloride promotes the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Cycloheximide promotes the reaction [Carbon Tetrachloride results in increased degradation of CYP2E1 protein]; Dimethyl Sulfoxide inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Edetic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Egtazic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Ethanol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; fomepizole inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Glycerol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; leupeptin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] Cycloheximide inhibits the reaction [pyridine results in increased activity of CYP2E1 protein]; Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP2E1 protein] |
CTD |
PMID:1968335 PMID:8531136 PMID:9143349 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp2f2 |
cytochrome P450, family 2, subfamily f, polypeptide 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA] |
CTD |
PMID:20187624 |
|
NCBI chr 7:26,819,380...26,833,085
Ensembl chr 7:26,819,334...26,833,085
|
|
G |
Dag1 |
dystroglycan 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DAG1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:108,082,060...108,141,176
Ensembl chr 9:108,081,833...108,141,157
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DCN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [plumbagin results in increased expression of DDIT3 protein] |
CTD |
PMID:31276663 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of DDIT4 protein [EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein |
CTD |
PMID:22689575 |
|
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
|
|
G |
Deaf1 |
DEAF1, transcription factor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DEAF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:140,877,089...140,918,758
Ensembl chr 7:140,877,093...140,907,603
|
|
G |
Degs1 |
delta 4-desaturase, sphingolipid 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DEGS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:182,103,529...182,110,366
Ensembl chr 1:182,103,337...182,110,369
|
|
G |
Dio2 |
deiodinase, iodothyronine, type II |
multiple interactions decreases activity |
ISO |
[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]; lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein] |
CTD |
PMID:11425850 PMID:26004626 |
|
NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812
|
|
G |
Dio3 |
deiodinase, iodothyronine type III |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DNAJB5 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:42,949,866...42,959,425
Ensembl chr 4:42,949,814...42,959,425
|
|
G |
Dnase1l3 |
deoxyribonuclease 1-like 3 |
increases expression |
EXP |
Cycloheximide results in increased expression of DNASE1L3 protein |
CTD |
PMID:15118903 |
|
NCBI chr14:14,475,014...14,504,586
Ensembl chr14:14,475,200...14,505,240
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of DNM1L mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DNM1L mRNA |
CTD |
PMID:19684285 |
|
NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
multiple interactions |
ISO |
[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein |
CTD |
PMID:19833194 |
|
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA |
CTD |
PMID:22483689 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
ISO |
[Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA mRNA; [Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA protein; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein] |
CTD |
PMID:20561571 |
|
NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein] |
CTD |
PMID:20561571 PMID:20716444 |
|
NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA] |
CTD |
PMID:12632255 PMID:22689575 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of EGFR mRNA Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] |
CTD |
PMID:15228094 PMID:26368632 PMID:30237564 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA] |
CTD |
PMID:12690110 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
Cycloheximide results in increased expression of EGR2 mRNA |
CTD |
PMID:19350554 |
|
NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [epimedokoreanin B results in increased phosphorylation of EIF2A protein]; Cycloheximide inhibits the reaction [Orlistat results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:17283163 PMID:36027945 |
|
NCBI chr 3:58,433,252...58,464,922
Ensembl chr 3:58,433,242...58,464,922
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [dimethylarsinous acid results in increased phosphorylation of EIF2AK3 protein] Cycloheximide inhibits the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [1,12-benzoperylene results in increased expression of EIF2AK3 mRNA]] |
CTD |
PMID:22425709 PMID:35182551 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases expression multiple interactions increases phosphorylation |
ISO EXP |
Cycloheximide results in increased expression of EIF2S1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of EIF2S1 mRNA Cycloheximide results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:19684285 PMID:24315374 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]] Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein] |
CTD |
PMID:22689575 PMID:25923732 |
|
NCBI chr 3:138,231,952...138,265,457
Ensembl chr 3:138,231,940...138,265,457
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]; Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4, gamma 1 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr16:20,491,457...20,511,633
Ensembl chr16:20,487,063...20,511,634
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of EIF4G3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:137,719,090...137,934,397
Ensembl chr 4:137,720,333...137,935,819
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of EIF5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr12:111,504,535...111,513,187
Ensembl chr12:111,504,450...111,513,186
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]] |
CTD |
PMID:25923732 |
|
NCBI chr 8:4,334,781...4,375,104
Ensembl chr 8:4,335,382...4,375,413
|
|
G |
Elf4 |
E74 like ETS transcription factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELF4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:47,499,926...47,552,009
Ensembl chr X:47,499,923...47,552,009
|
|
G |
Elk1 |
ELK1, member of ETS oncogene family |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of ELK1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ELK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:20,799,634...20,816,847
Ensembl chr X:20,799,634...20,816,847
|
|
G |
Eln |
elastin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Okadaic Acid results in decreased expression of ELN mRNA] |
CTD |
PMID:8997264 |
|
NCBI chr 5:134,731,449...134,776,300
Ensembl chr 5:134,731,447...134,776,177
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
decreases expression multiple interactions |
EXP |
Cycloheximide results in decreased expression of ELOVL3 mRNA Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of ELOVL3 mRNA] |
CTD |
PMID:17726147 |
|
NCBI chr19:46,120,336...46,124,133
Ensembl chr19:46,120,336...46,124,133
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of ENC1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr13:97,377,613...97,389,548
Ensembl chr13:97,377,613...97,389,542
|
|
G |
Endog |
endonuclease G |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ENDOG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:30,061,525...30,064,057
Ensembl chr 2:30,061,505...30,064,081
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]; MALAT1 mRNA inhibits the reaction [Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]] Cycloheximide results in decreased expression of EPAS1 protein |
CTD |
PMID:23958427 PMID:26735578 |
|
NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] |
CTD |
PMID:10756076 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Epyc |
epiphycan |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EPYC mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:97,479,930...97,517,770
Ensembl chr10:97,479,930...97,518,316
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression increases degradation |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA; Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]; PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] Cycloheximide results in decreased expression of ERBB2 mRNA; Cycloheximide results in decreased expression of ERBB2 protein |
CTD |
PMID:15072547 PMID:15228094 PMID:20379846 PMID:25866362 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15228094 |
|
NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Cycloheximide results in increased expression of EREG mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of ERN1 protein] |
CTD |
PMID:26784903 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions decreases expression |
ISO |
bisphenol A promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; Estradiol promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein] |
CTD |
PMID:24586459 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]] |
CTD |
PMID:15207704 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of ESRRA protein HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein] |
CTD |
PMID:34524571 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Ext2 |
exostosin glycosyltransferase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EXT2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:93,525,978...93,652,913
Ensembl chr 2:93,491,373...93,652,913
|
|
G |
F12 |
coagulation factor XII (Hageman factor) |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of F12 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:55,565,771...55,574,617
Ensembl chr13:55,565,771...55,574,606
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein] |
CTD |
PMID:14630613 |
|
NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
F3 |
coagulation factor III |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in decreased expression of F3 mRNA] |
CTD |
PMID:11876987 |
|
NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases response to substance |
ISO EXP |
Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein] Cycloheximide results in increased susceptibility to FAS protein |
CTD |
PMID:8932996 PMID:12760867 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FASLG mRNA] [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein |
CTD |
PMID:11007951 PMID:19833194 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Calcitriol results in decreased expression of FASN mRNA] |
CTD |
PMID:12798352 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fbl |
fibrillarin |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FBL mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:27,868,293...27,878,701
Ensembl chr 7:27,869,135...27,878,694
|
|
G |
Fbxw7 |
F-box and WD-40 domain protein 7 |
multiple interactions |
ISO EXP |
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]] |
CTD |
PMID:24457827 PMID:25897075 |
|
NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
|
|
G |
Fga |
fibrinogen alpha chain |
decreases expression |
ISO |
Cycloheximide results in decreased expression of FGA protein |
CTD |
PMID:444225 |
|
NCBI chr 3:82,933,460...82,940,934
Ensembl chr 3:82,933,383...82,940,934
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
ISO |
Cycloheximide results in decreased expression of FGB protein |
CTD |
PMID:444225 |
|
NCBI chr 3:82,949,553...82,957,170
Ensembl chr 3:82,947,448...82,957,170
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:9798919 PMID:15654655 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA] |
CTD |
PMID:12805413 |
|
NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734
|
|
G |
Fgl2 |
fibrinogen-like protein 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FGL2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:21,577,671...21,583,384
Ensembl chr 5:21,577,640...21,583,372
|
|
G |
Fhit |
fragile histidine triad gene |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FHIT mRNA |
CTD |
PMID:19684285 |
|
NCBI chr14:11,307,718...12,919,681
Ensembl chr14:11,307,738...12,919,681
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr X:55,776,569...55,838,704
Ensembl chr X:55,777,147...55,838,706
|
|
G |
Flt3 |
FMS-like tyrosine kinase 3 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of FLT3 protein mutant form |
CTD |
PMID:32284743 |
|
NCBI chr 5:147,267,551...147,337,299
Ensembl chr 5:147,267,551...147,337,299
|
|
G |
Fmo3 |
flavin containing monooxygenase 3 |
increases expression |
EXP |
Cycloheximide results in increased expression of FMO3 mRNA |
CTD |
PMID:20570689 |
|
NCBI chr 1:162,781,368...162,812,097
Ensembl chr 1:162,781,369...162,812,097
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FMR1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:67,722,144...67,761,569
Ensembl chr X:67,722,147...67,761,569
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Estradiol results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Genistein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of FOS protein]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA] Cycloheximide results in increased expression of FOS mRNA [Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA; Cadmium Chloride promotes the reaction [Cycloheximide results in increased expression of FOS mRNA]; Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of FOS protein]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA] Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein] |
CTD |
PMID:1696944 PMID:9094091 PMID:9417049 PMID:9650640 PMID:12632255 PMID:15090535 PMID:15136564 PMID:20495008 More...
|
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Frk |
fyn-related kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FRK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:34,359,396...34,487,530
Ensembl chr10:34,359,395...34,487,274
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FST mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:114,588,798...114,595,522
Ensembl chr13:114,588,826...114,595,487
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FUT4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:14,659,755...14,663,418
Ensembl chr 9:14,659,616...14,663,689
|
|
G |
Fzd7 |
frizzled class receptor 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FZD7 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:59,521,306...59,526,114
Ensembl chr 1:59,521,583...59,526,114
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of G6PD protein] |
CTD |
PMID:1978808 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GALNT1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:24,338,401...24,419,873
Ensembl chr18:24,338,401...24,419,875
|
|
G |
Gas1 |
growth arrest specific 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GAS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:60,322,219...60,325,179
Ensembl chr13:60,322,219...60,325,179
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP ISO |
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLC mRNA]; Cycloheximide inhibits the reaction [diphenylarsinic acid results in increased expression of GCLC protein] Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein] |
CTD |
PMID:17628625 PMID:19328227 PMID:24437944 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLM mRNA] |
CTD |
PMID:19328227 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA]; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein]; Cycloheximide inhibits the reaction [troglitazone results in increased expression of GDF15 mRNA] |
CTD |
PMID:14662774 PMID:18801729 |
|
NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Cycloheximide results in decreased expression of GJA1 protein]; Cycloheximide promotes the reaction [Benzo(a)pyrene results in decreased expression of GJA1 protein] |
CTD |
PMID:34283317 PMID:36863560 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gpaa1 |
GPI anchor attachment protein 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of GPAA1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of GPAA1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:76,215,494...76,219,099
Ensembl chr15:76,215,431...76,219,107
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GPR37 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:25,668,522...25,689,979
Ensembl chr 6:25,665,877...25,690,728
|
|
G |
Grm5 |
glutamate receptor, metabotropic 5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA]; Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein] |
CTD |
PMID:11665859 |
|
NCBI chr 7:87,233,212...87,784,271
Ensembl chr 7:87,233,376...87,784,115
|
|
G |
Grn |
granulin |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GRN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:102,321,333...102,327,635
Ensembl chr11:102,321,141...102,327,874
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GSK3B mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gsta3 |
glutathione S-transferase, alpha 3 |
decreases expression multiple interactions |
EXP |
Cycloheximide results in decreased expression of GSTA1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]]; Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA] |
CTD |
PMID:16243960 |
|
NCBI chr 1:21,310,837...21,335,885
Ensembl chr 1:21,310,813...21,335,885
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Cycloheximide results in increased expression of HBEGF mRNA |
CTD |
PMID:15228094 |
|
NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions |
ISO |
HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein] |
CTD |
PMID:34524571 |
|
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions increases degradation decreases expression |
ISO EXP |
[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with Oxygen deficiency] affects the expression of HIF1A protein; [Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein; Cycloheximide affects the reaction [[Apigenin co-treated with Oxygen deficiency] affects the expression of HIF1A protein]; Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein]; Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of HIF1A protein]; Cycloheximide inhibits the reaction [zinc chloride results in increased expression of HIF1A protein alternative form]; Cycloheximide promotes the reaction [Cobalt results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [sodium arsenite inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; genipin affects the reaction [[Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose co-treated with Cycloheximide] results in decreased expression of HIF1A protein]; scutellarin promotes the reaction [Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; sodium arsenite inhibits the reaction [Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]] Cycloheximide results in increased degradation of HIF1A protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Polystyrenes analog results in increased expression of HIF1A protein] Cycloheximide results in decreased expression of HIF1A Cycloheximide results in decreased expression of HIF1A protein Cycloheximide promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein] |
CTD |
PMID:11641398 PMID:11739637 PMID:19958256 PMID:20524035 PMID:22537771 PMID:23593480 PMID:24188932 PMID:24221993 PMID:24497960 PMID:25192544 PMID:27286880 PMID:29630948 PMID:30266538 PMID:31285264 PMID:31850806 PMID:34717917 PMID:34900531 PMID:35513012 PMID:36709824 More...
|
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein] Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [puerarin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Triterpenes analog results in increased expression of HMOX1 protein] Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein] |
CTD |
PMID:9747510 PMID:12441344 PMID:12472888 PMID:15118350 PMID:15588712 PMID:15876423 PMID:15965080 PMID:16647178 PMID:17002867 PMID:18357586 PMID:19781563 PMID:20060010 PMID:20833156 PMID:21840424 PMID:24255720 PMID:24437944 PMID:25239868 PMID:26385185 PMID:30076913 PMID:35821281 More...
|
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
increases expression |
ISO |
Cycloheximide results in increased expression of HNRNPH2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:133,501,928...133,507,809
Ensembl chr X:133,501,928...133,507,809
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Glycine results in increased expression of HNRNPK protein] |
CTD |
PMID:24990929 |
|
NCBI chr13:58,538,946...58,551,157
Ensembl chr13:58,538,956...58,551,157
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [tributyltin results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [triphenyltin chloride results in increased expression of HSD11B2 mRNA] |
CTD |
PMID:31927052 |
|
NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620
|
|
G |
Hsf1 |
heat shock factor 1 |
decreases activity |
ISO |
Cycloheximide results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [GIF 0010 results in increased expression of HSPA5 mRNA]; Cycloheximide inhibits the reaction [lead acetate results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Mercuric Chloride results in increased expression of HSPA5 protein] Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [plumbagin results in increased expression of HSPA5 protein] |
CTD |
PMID:9742210 PMID:17915553 PMID:26784903 PMID:31276663 PMID:34560123 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of HTATIP2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:49,408,761...49,423,748
Ensembl chr 7:49,408,863...49,423,723
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] Cycloheximide results in decreased expression of ICAM1 protein |
CTD |
PMID:16087364 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of IER3 mRNA |
CTD |
PMID:16849584 |
|
NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] |
CTD |
PMID:12070711 PMID:16087364 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ift27 |
intraflagellar transport 27 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IFT27 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr15:78,043,660...78,058,281
Ensembl chr15:78,043,663...78,058,307
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP ISO |
Cycloheximide inhibits the reaction [IGF1 protein affects the metabolism of 1,2-diacylglycerol] IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein] |
CTD |
PMID:2120207 PMID:26687534 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein] |
CTD |
PMID:36822301 |
|
NCBI chr 6:49,062,152...49,200,225
Ensembl chr 6:49,062,157...49,191,891
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of IGFBP4 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression decreases response to substance |
EXP ISO |
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA] Cycloheximide results in increased expression of IL10 mRNA IL10 protein results in decreased susceptibility to Cycloheximide |
CTD |
PMID:19395591 PMID:22183712 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Glucose results in increased secretion of IL17A protein] |
CTD |
PMID:18310510 |
|
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] |
CTD |
PMID:18660453 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1A mRNA Cycloheximide results in increased expression of IL1A mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1B mRNA; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL1B protein]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of IL1B protein modified form] Cycloheximide results in increased expression of IL1B mRNA Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:8071060 PMID:9606035 PMID:11112151 PMID:11286988 PMID:19684285 PMID:26901245 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il5 |
interleukin 5 |
decreases expression multiple interactions |
EXP |
Cycloheximide results in decreased expression of IL5 protein T0901317 inhibits the reaction [Cycloheximide results in decreased expression of IL5 protein] |
CTD |
PMID:23150660 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion increases expression decreases secretion |
ISO EXP |
Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL6 protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] Cycloheximide results in decreased secretion of IL6 protein |
CTD |
PMID:8071060 PMID:11216681 PMID:12185005 PMID:21146893 PMID:24771768 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Il6st |
interleukin 6 signal transducer |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL6ST mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:112,600,604...112,643,394
Ensembl chr13:112,600,604...112,646,620
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:19070612 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein] |
CTD |
PMID:22537771 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IQGAP1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:80,361,331...80,453,288
Ensembl chr 7:80,361,331...80,475,722
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of IRS1 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IRS1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Itgb3 |
integrin beta 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302
|
|
G |
Itgb6 |
integrin beta 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB6 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] |
CTD |
PMID:11007951 PMID:21303922 |
|
NCBI chr 2:60,428,636...60,553,005
Ensembl chr 2:60,428,636...60,552,987
|
|
G |
Itpk1 |
inositol 1,3,4-triphosphate 5/6 kinase |
multiple interactions |
ISO |
ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein] |
CTD |
PMID:12925536 |
|
NCBI chr12:102,534,842...102,671,128
Ensembl chr12:102,534,841...102,671,189
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Ethanol results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITPR1 mRNA] |
CTD |
PMID:11007951 PMID:17241155 |
|
NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070
|
|
G |
Ivns1abp |
influenza virus NS1A binding protein |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Doxorubicin results in decreased expression of IVNS1ABP mRNA] |
CTD |
PMID:17016628 |
|
NCBI chr 1:151,220,237...151,240,196
Ensembl chr 1:151,220,228...151,240,173
|
|
G |
Jun |
jun proto-oncogene |
increases stability multiple interactions increases phosphorylation |
ISO EXP |
Cycloheximide results in increased stability of JUN protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein] Cycloheximide promotes the reaction [Cadmium results in increased expression of JUN mRNA] Cycloheximide results in increased phosphorylation of JUN protein |
CTD |
PMID:1696944 PMID:9751194 PMID:12169099 PMID:23593480 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kank1 |
KN motif and ankyrin repeat domains 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KANK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr19:25,214,146...25,411,861
Ensembl chr19:25,214,339...25,411,860
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein] |
CTD |
PMID:16696851 |
|
NCBI chr16:22,876,970...22,900,828
Ensembl chr16:22,876,615...22,900,828
|
|
G |
Kras |
Kirsten rat sarcoma viral oncogene homolog |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965
|
|
G |
Kremen1 |
kringle containing transmembrane protein 1 |
affects response to substance |
ISO |
KREMEN1 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr11:5,141,551...5,212,220
Ensembl chr11:5,141,552...5,211,558
|
|
G |
Krt13 |
keratin 13 |
multiple interactions |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of KRT13 mRNA |
CTD |
PMID:16849584 |
|
NCBI chr11:100,008,153...100,012,392
Ensembl chr11:100,008,153...100,012,392
|
|
G |
Krtcap2 |
keratinocyte associated protein 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KRTCAP2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:89,153,201...89,157,036
Ensembl chr 3:89,153,273...89,157,213
|
|
G |
Lck |
lymphocyte protein tyrosine kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:129,442,142...129,467,415
Ensembl chr 4:129,442,137...129,467,434
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [Quercetin results in increased expression of LDLR protein] Cycloheximide results in decreased expression of LDLR protein |
CTD |
PMID:22388943 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein] |
CTD |
PMID:31199479 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lepr |
leptin receptor |
multiple interactions decreases expression |
EXP |
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein] |
CTD |
PMID:31199479 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Lgals3 |
lectin, galactose binding, soluble 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of LGALS3 protein] |
CTD |
PMID:21821001 |
|
NCBI chr14:47,611,317...47,623,624
Ensembl chr14:47,605,208...47,623,617
|
|
G |
Lhb |
luteinizing hormone beta |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA] |
CTD |
PMID:11416027 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Lmo7 |
LIM domain only 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LMO7 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr14:101,967,353...102,172,144
Ensembl chr14:101,967,386...102,172,146
|
|
G |
Lpxn |
leupaxin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LPXN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr19:12,773,251...12,811,177
Ensembl chr19:12,773,557...12,811,171
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
increases degradation multiple interactions |
ISO |
Cycloheximide results in increased degradation of MAF1 protein Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein]; CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr15:76,235,494...76,238,578
Ensembl chr15:76,235,494...76,238,580
|
|
G |
Malat1 |
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) |
multiple interactions |
ISO |
MALAT1 mRNA inhibits the reaction [Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]]; sodium arsenite inhibits the reaction [Cycloheximide results in decreased expression of MALAT1 protein] |
CTD |
PMID:26735578 |
|
NCBI chr19:5,845,718...5,852,700
Ensembl chr19:5,845,717...5,852,706
|
|
G |
Map2k1 |
mitogen-activated protein kinase kinase 1 |
multiple interactions increases activity |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA] Cycloheximide results in increased activity of MAP2K1 protein |
CTD |
PMID:23237828 |
|
NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Cycloheximide results in increased phosphorylation of MAPK1 protein TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]] Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide promotes the reaction [[sodium arsenite co-treated with Hydrogen Peroxide] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of MAPK14 protein] |
CTD |
PMID:17507666 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
Cycloheximide results in increased phosphorylation of MAPK3 protein TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]] Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide promotes the reaction [sodium arsenite promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MAPK7 mRNA; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK7 mRNA] Cycloheximide results in increased expression of MAPK7 mRNA |
CTD |
PMID:11007951 PMID:19684285 |
|
NCBI chr11:61,379,638...61,385,101
Ensembl chr11:61,379,638...61,385,232
|
|
G |
Mapkapk3 |
mitogen-activated protein kinase-activated protein kinase 3 |
affects response to substance |
ISO |
MAPKAPK3 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 9:107,132,125...107,167,082
Ensembl chr 9:107,132,126...107,167,076
|
|
G |
Mbp |
myelin basic protein |
affects expression |
ISO |
Cycloheximide affects the expression of MBP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [Resveratrol co-treated with Clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein] |
CTD |
PMID:14982947 PMID:21880625 PMID:24924397 PMID:25408576 PMID:25923732 PMID:35561756 More...
|
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Mdk |
midkine |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MDK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:91,760,149...91,762,348
Ensembl chr 2:91,760,150...91,762,642
|
|
G |
Mir21a |
microRNA 21a |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of MIR21 mRNA Cycloheximide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [Estradiol results in decreased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA] |
CTD |
PMID:19264808 PMID:23052036 |
|
NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
|
|
G |
Mir22hg |
Mir22 host gene (non-protein coding) |
multiple interactions |
ISO |
Cycloheximide results in increased stability of and results in increased expression of MIR22HG mRNA |
CTD |
PMID:24036268 |
|
NCBI chr11:75,352,365...75,357,516
Ensembl chr11:75,352,365...75,357,502
|
|
G |
Mitf |
melanogenesis associated transcription factor |
multiple interactions |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein]; [Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein |
CTD |
PMID:30849679 |
|
NCBI chr 6:97,783,966...97,998,321
Ensembl chr 6:97,784,013...97,998,310
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased expression of MMP13 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MMP13 mRNA Cycloheximide inhibits the reaction [Tretinoin results in increased expression of MMP13 mRNA] |
CTD |
PMID:16350840 PMID:19684285 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MMP1 mRNA] |
CTD |
PMID:15075337 PMID:19136476 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of MMP2 mRNA] |
CTD |
PMID:26621329 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mnx1 |
motor neuron and pancreas homeobox 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MNX1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:29,678,821...29,683,468
Ensembl chr 5:29,678,032...29,683,468
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MPG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:32,176,505...32,182,702
Ensembl chr11:32,176,505...32,182,700
|
|
G |
Mrps7 |
mitchondrial ribosomal protein S7 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of MRPS7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of MRPS7 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:115,494,966...115,498,862
Ensembl chr11:115,494,751...115,498,862
|
|
G |
Msh3 |
mutS homolog 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MSH3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:92,348,387...92,491,515
Ensembl chr13:92,348,380...92,491,511
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA] |
CTD |
PMID:9614211 |
|
NCBI chr 8:39,996,284...40,095,790
Ensembl chr 8:40,034,726...40,095,714
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions increases expression |
EXP |
2-tert-butylhydroquinone promotes the reaction [Cycloheximide results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]; MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA] |
CTD |
PMID:14998373 PMID:19276070 |
|
NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955
|
|
G |
Mtch2 |
mitochondrial carrier 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTCH2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:90,677,434...90,697,154
Ensembl chr 2:90,677,499...90,697,154
|
|
G |
Mterf3 |
mitochondrial transcription termination factor 3 |
multiple interactions decreases expression |
ISO |
Ammonium Chloride inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein] |
CTD |
PMID:35904214 |
|
NCBI chr13:67,053,520...67,081,148
Ensembl chr13:67,055,032...67,081,152
|
|
G |
Mtf1 |
metal response element binding transcription factor 1 |
multiple interactions |
EXP |
MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA] |
CTD |
PMID:19276070 |
|
NCBI chr 4:124,696,342...124,743,593
Ensembl chr 4:124,695,897...124,743,593
|
|
G |
Mtmr7 |
myotubularin related protein 7 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of MTMR7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTMR7 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:41,003,184...41,088,210
Ensembl chr 8:41,004,136...41,087,840
|
|
G |
Mxd1 |
MAX dimerization protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MXD1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:86,624,026...86,646,099
Ensembl chr 6:86,624,024...86,646,143
|
|
G |
Mxd3 |
Max dimerization protein 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MXD3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr13:55,472,983...55,477,937
Ensembl chr13:55,472,981...55,477,636
|
|
G |
Myc |
myelocytomatosis oncogene |
multiple interactions |
EXP ISO |
arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] Cycloheximide promotes the reaction [Cadmium results in increased expression of MYC mRNA] Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of MYC protein] |
CTD |
PMID:1696944 PMID:23593480 PMID:24457827 PMID:31285264 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Mylk |
myosin, light polypeptide kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein] |
CTD |
PMID:15701621 |
|
NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790
|
|
G |
Myo1d |
myosin ID |
affects response to substance |
ISO |
MYO1D gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr11:80,372,945...80,670,881
Ensembl chr11:80,372,952...80,670,851
|
|
G |
Nbr1 |
NBR1, autophagy cargo receptor |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of NBR1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NBR1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:101,442,933...101,472,777
Ensembl chr11:101,442,975...101,472,777
|
|
G |
Ndrg1 |
N-myc downstream regulated gene 1 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of NDRG1 protein] |
CTD |
PMID:28906492 |
|
NCBI chr15:66,801,167...66,841,490
Ensembl chr15:66,801,167...66,841,489
|
|
G |
Nedd4 |
neural precursor cell expressed, developmentally down-regulated 4 |
decreases expression multiple interactions |
EXP |
Cycloheximide results in decreased expression of NEDD4 protein Melatonin promotes the reaction [Cycloheximide results in decreased expression of NEDD4 protein] |
CTD |
PMID:31325559 |
|
NCBI chr 9:72,569,613...72,657,133
Ensembl chr 9:72,569,628...72,657,134
|
|
G |
Nefh |
neurofilament, heavy polypeptide |
decreases expression |
ISO |
Cycloheximide results in decreased expression of NEFH mRNA |
CTD |
PMID:19146868 |
|
NCBI chr11:4,888,754...4,898,064
Ensembl chr11:4,888,754...4,898,064
|
|
G |
Nefl |
neurofilament, light polypeptide |
decreases expression |
ISO |
Cycloheximide results in decreased expression of NEFL mRNA |
CTD |
PMID:19146868 |
|
NCBI chr14:68,321,312...68,326,544
Ensembl chr14:68,321,312...68,326,544
|
|
G |
Nek2 |
NIMA (never in mitosis gene a)-related expressed kinase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NEK2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:191,553,622...191,565,161
Ensembl chr 1:191,553,556...191,565,162
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions decreases expression |
EXP ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of NFE2L2 protein]; Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]; Exenatide inhibits the reaction [Cycloheximide results in decreased expression of NFE2L2 protein] [SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; Curcumin inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein] |
CTD |
PMID:12441344 PMID:14510636 PMID:15322212 PMID:22019695 PMID:22197970 PMID:25896339 PMID:27286880 PMID:27939242 PMID:34758851 More...
|
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
affects localization increases expression multiple interactions |
ISO EXP |
Cycloheximide affects the localization of NFKB1 protein Cycloheximide results in increased expression of NFKB1 mRNA Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] |
CTD |
PMID:16637064 PMID:21146893 PMID:24457827 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions increases degradation decreases expression |
ISO |
Cycloheximide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKBIA mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NFKBIA protein]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in decreased expression of NFKBIA protein]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased degradation of NFKBIA protein] |
CTD |
PMID:11007951 PMID:15330761 PMID:16637064 PMID:21692457 PMID:22258905 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein] |
CTD |
PMID:20495008 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of NLRP3 protein] |
CTD |
PMID:26901245 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Raloxifene Hydrochloride co-treated with 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid] results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS2 mRNA] |
CTD |
PMID:10760090 PMID:11007951 PMID:28138957 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Npy1r |
neuropeptide Y receptor Y1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:67,149,595...67,159,452
Ensembl chr 8:67,149,844...67,159,444
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
decreases expression multiple interactions |
EXP ISO |
Cycloheximide results in decreased expression of NQO1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]]; Cycloheximide inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [arsenite results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Cadmium results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Chromium results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA] Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein] |
CTD |
PMID:14510636 PMID:16243960 PMID:18474416 PMID:24437944 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:18787026 |
|
NCBI chr X:85,235,381...85,239,553
Ensembl chr X:85,235,370...85,239,553
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NR1H3 mRNA Cycloheximide results in increased expression of NR1H3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
EXP ISO |
Cycloheximide inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone binds to NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein] Cycloheximide promotes the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA] |
CTD |
PMID:21569845 PMID:31778773 |
|
NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA] |
CTD |
PMID:11416027 |
|
NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
|
|
G |
Nucks1 |
nuclear casein kinase and cyclin-dependent kinase substrate 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NUCKS1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:131,838,196...131,864,059
Ensembl chr 1:131,838,272...131,864,059
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Paraquat results in increased activity of ODC1 protein] |
CTD |
PMID:7662713 |
|
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of OPA1 protein alternative form] |
CTD |
PMID:20678484 |
|
NCBI chr16:29,398,099...29,481,924
Ensembl chr16:29,398,152...29,473,702
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of OPRK1 mRNA Cycloheximide results in increased expression of OPRK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:5,658,673...5,676,357
Ensembl chr 1:5,658,689...5,676,354
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of OPRM1 mRNA] |
CTD |
PMID:16434616 |
|
NCBI chr10:6,708,593...6,988,209
Ensembl chr10:6,708,506...6,988,198
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone results in increased expression of ORM1 mRNA] |
CTD |
PMID:20599767 |
|
NCBI chr 4:63,262,793...63,266,400
Ensembl chr 4:63,262,797...63,266,400
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
multiple interactions |
ISO |
PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] |
CTD |
PMID:20379846 |
|
NCBI chr10:128,393,635...128,401,803
Ensembl chr10:128,393,635...128,401,856
|
|
G |
Pappa |
pregnancy-associated plasma protein A |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PAPPA mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PAPPA mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:65,041,993...65,276,776
Ensembl chr 4:65,042,411...65,275,746
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions increases cleavage |
ISO |
[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein] Cycloheximide results in increased cleavage of PARP1 protein Cycloheximide inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein] |
CTD |
PMID:12925536 PMID:15147502 PMID:16051428 PMID:18222423 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pax3 |
paired box 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PAX3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:78,077,904...78,173,773
Ensembl chr 1:78,077,904...78,173,771
|
|
G |
Pcgf1 |
polycomb group ring finger 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PCGF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:83,047,573...83,057,836
Ensembl chr 6:83,054,850...83,057,836
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of PCK1 mRNA] |
CTD |
PMID:9518257 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Vitamin K 3 results in decreased expression of PCNA protein] |
CTD |
PMID:21533478 |
|
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
|
|
G |
Pdcd2 |
programmed cell death 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PDCD2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:15,739,472...15,747,560
Ensembl chr17:15,739,470...15,747,563
|
|
G |
Pi4ka |
phosphatidylinositol 4-kinase alpha |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PI4KA mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:17,098,215...17,224,178
Ensembl chr16:17,098,215...17,224,178
|
|
G |
Pigh |
phosphatidylinositol glycan anchor biosynthesis, class H |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGH mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:79,127,443...79,136,478
Ensembl chr12:79,127,438...79,136,425
|
|
G |
Pigk |
phosphatidylinositol glycan anchor biosynthesis, class K |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:152,419,718...152,548,705
Ensembl chr 3:152,419,737...152,686,045
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase catalytic subunit type 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3C3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr18:30,390,441...30,481,179
Ensembl chr18:30,405,800...30,481,179
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3CG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:32,223,128...32,258,675
Ensembl chr12:32,223,472...32,258,658
|
|
G |
Pilrb2 |
paired immunoglobin-like type 2 receptor beta 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PILRB mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 5:137,864,083...137,870,083
Ensembl chr 5:137,864,089...137,870,077
|
|
G |
Pla2g1b |
phospholipase A2, group IB, pancreas |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G1B mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:115,604,201...115,612,781
Ensembl chr 5:115,604,321...115,612,781
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dexamethasone inhibits the reaction [Zymosan results in increased activity of PLA2G4A protein]] |
CTD |
PMID:10874129 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Plat |
plasminogen activator, tissue |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Isoproterenol results in increased expression of PLAT mRNA] |
CTD |
PMID:2477232 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA; [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA Cycloheximide results in increased expression of PLAUR mRNA |
CTD |
PMID:12070711 |
|
NCBI chr 7:24,161,857...24,175,393
Ensembl chr 7:24,161,909...24,175,393
|
|
G |
Pld3 |
phospholipase D family member 3 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PLD3 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:27,231,090...27,252,511
Ensembl chr 7:27,231,425...27,252,643
|
|
G |
Pln |
phospholamban |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PLN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:53,213,782...53,222,095
Ensembl chr10:53,213,763...53,222,083
|
|
G |
Plp1 |
proteolipid protein (myelin) 1 |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Tretinoin results in increased expression of PLP1 mRNA] Cycloheximide results in increased expression of PLP1 mRNA |
CTD |
PMID:19450544 |
|
NCBI chr X:135,720,897...135,739,331
Ensembl chr X:135,723,420...135,740,482
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Fenretinide results in increased expression of PMAIP1 protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PMAIP1 protein] |
CTD |
PMID:17216584 |
|
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
|
|
G |
Pml |
promyelocytic leukemia |
decreases degradation multiple interactions |
ISO |
Cycloheximide results in decreased degradation of PML protein modified form Cycloheximide inhibits the reaction [arsenic trioxide results in increased degradation of PML protein] |
CTD |
PMID:20943951 PMID:26049103 |
|
NCBI chr 9:58,125,359...58,157,077
Ensembl chr 9:58,125,359...58,157,069
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PNPLA2 protein] |
CTD |
PMID:18643838 |
|
NCBI chr 7:141,035,101...141,040,656
Ensembl chr 7:141,035,111...141,040,656
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein] |
CTD |
PMID:20380879 |
|
NCBI chr 8:3,565,341...3,594,267
Ensembl chr 8:3,565,384...3,594,267
|
|
G |
Pomc |
pro-opiomelanocortin-alpha |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [POMC protein modified form results in increased chemical synthesis of Adrenal Cortex Hormones] |
CTD |
PMID:2993719 |
|
NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases expression |
ISO |
POR protein mutant form promotes the reaction [Cycloheximide results in decreased expression of POR protein] |
CTD |
PMID:27496950 |
|
NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Cobalt results in increased expression of POU5F1 protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of POU5F1 protein] |
CTD |
PMID:24497960 |
|
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Ppan |
peter pan homolog |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPAN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:20,799,471...20,803,475
Ensembl chr 9:20,799,471...20,803,474
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
multiple interactions decreases expression |
ISO |
arsenite inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; Cycloheximide affects the reaction [arsenite results in increased expression of PPP1R15A protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PPP1R15A protein] |
CTD |
PMID:29109149 |
|
NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692
|
|
G |
Ppp3cb |
protein phosphatase 3, catalytic subunit, beta isoform |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPP3CB mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr14:20,549,432...20,596,641
Ensembl chr14:20,549,432...20,596,641
|
|
G |
Ppp4r3b |
protein phosphatase 4 regulatory subunit 3B |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPP4R3B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:29,118,053...29,170,797
Ensembl chr11:29,122,890...29,170,797
|
|
G |
Prdx4 |
peroxiredoxin 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRDX4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:154,106,914...154,125,268
Ensembl chr X:154,106,914...154,123,750
|
|
G |
Prkcb |
protein kinase C, beta |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of PRKCB mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PRKCB mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCD protein] |
CTD |
PMID:11118818 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCE protein] |
CTD |
PMID:11118818 |
|
NCBI chr17:86,472,631...86,965,347
Ensembl chr17:86,475,213...86,965,347
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRKCZ mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:155,344,579...155,445,856
Ensembl chr 4:155,344,586...155,445,818
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973
|
|
G |
Psen2 |
presenilin 2 |
multiple interactions |
ISO |
Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr 1:180,054,569...180,091,030
Ensembl chr 1:180,054,569...180,091,003
|
|
G |
Psmd1 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 |
multiple interactions |
ISO |
PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 1:85,992,341...86,067,017
Ensembl chr 1:85,992,109...86,066,873
|
|
G |
Psme3 |
proteaseome (prosome, macropain) activator subunit 3 (PA28 gamma, Ki) |
multiple interactions |
ISO |
PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein] |
CTD |
PMID:31645432 |
|
NCBI chr11:101,206,090...101,214,363
Ensembl chr11:101,207,039...101,214,363
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Cycloheximide affects the reaction [sodium arsenite affects the expression of PTEN protein]; Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; Cycloheximide inhibits the reaction [Rosiglitazone results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:33256086 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein]; Cycloheximide inhibits the reaction [Tretinoin results in increased expression of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] Cycloheximide results in increased expression of PTGS2 mRNA |
CTD |
PMID:7575673 PMID:11112151 PMID:11286988 PMID:16696851 PMID:16894348 PMID:22767315 More...
|
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptn |
pleiotrophin |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PTN mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:36,691,863...36,787,114
Ensembl chr 6:36,691,864...36,787,155
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4a1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Cycloheximide promotes the reaction [Estradiol results in increased expression of PTP4A1 mRNA] |
CTD |
PMID:19146866 |
|
NCBI chr 1:30,979,384...30,988,838
Ensembl chr 1:30,979,383...30,988,390 Ensembl chr 1:30,979,383...30,988,390
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4a3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTP4A3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:73,594,991...73,629,075
Ensembl chr15:73,594,994...73,630,615
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] |
CTD |
PMID:17623046 |
|
NCBI chr 7:46,727,543...46,783,774
Ensembl chr 7:46,727,543...46,783,432
|
|
G |
Rabepk |
Rab9 effector protein with kelch motifs |
affects response to substance |
ISO |
RABEPK gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 2:34,662,946...34,690,200
Ensembl chr 2:34,667,568...34,689,924
|
|
G |
Rapgef1 |
Rap guanine nucleotide exchange factor (GEF) 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RAPGEF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:29,509,732...29,630,376
Ensembl chr 2:29,509,732...29,630,990
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Tretinoin results in increased expression of RARB mRNA] Cycloheximide results in increased expression of RARB mRNA |
CTD |
PMID:19450544 |
|
NCBI chr14:5,387,365...6,038,924
Ensembl chr14:5,650,540...6,038,924
|
|
G |
Rarres2 |
retinoic acid receptor responder (tazarotene induced) 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of RARRES2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RARRES2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:48,546,630...48,549,778
Ensembl chr 6:48,546,630...48,549,723
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]] |
CTD |
PMID:20100483 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RBL1 mRNA]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]] |
CTD |
PMID:11007951 PMID:20100483 |
|
NCBI chr 2:156,987,813...157,046,454
Ensembl chr 2:156,987,813...157,046,454
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RBPJ protein [PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; Cycloheximide inhibits the reaction [Ammonium Chloride results in increased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr 5:53,713,121...53,814,787
Ensembl chr 5:53,623,494...53,814,704
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions affects localization |
ISO |
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein] Cycloheximide affects the localization of RELA protein |
CTD |
PMID:16637064 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Ren1 |
renin 1 structural |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased secretion of REN protein] |
CTD |
PMID:9203624 |
|
NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
ISO |
Cycloheximide results in decreased expression of RET protein |
CTD |
PMID:17555550 |
|
NCBI chr 6:118,128,709...118,174,705
Ensembl chr 6:118,128,706...118,174,679
|
|
G |
Rgn |
regucalcin |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA] |
CTD |
PMID:18327666 |
|
NCBI chr X:20,413,980...20,428,328
Ensembl chr X:20,416,026...20,428,328
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [cytotoxic necrotizing factor type 1 results in increased expression of RHOB protein] |
CTD |
PMID:23732113 |
|
NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RHOC protein RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO EXP |
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] Cycloheximide inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA] |
CTD |
PMID:25897075 PMID:29576526 |
|
NCBI chr15:6,737,827...6,829,882
Ensembl chr15:6,737,860...6,829,882
|
|
G |
Rnf168 |
ring finger protein 168 |
multiple interactions |
ISO |
RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr16:32,096,279...32,120,260
Ensembl chr16:32,096,277...32,120,252
|
|
G |
Rnf4 |
ring finger protein 4 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RNF4 protein Cycloheximide inhibits the reaction [TAK-243 affects the localization of RNF4 protein] |
CTD |
PMID:20943951 PMID:31285264 |
|
NCBI chr 5:34,493,594...34,510,789
Ensembl chr 5:34,493,633...34,512,973
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RPS27L mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:66,851,906...66,856,804
Ensembl chr 9:66,853,368...66,856,798
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:22689575 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Rrm2 |
ribonucleotide reductase M2 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA] |
CTD |
PMID:22403396 |
|
NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145
|
|
G |
Runx2 |
runt related transcription factor 2 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA] |
CTD |
PMID:15962303 PMID:18327666 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:90,511,077...90,513,349
Ensembl chr 3:90,511,078...90,513,352
|
|
G |
S100b |
S100 protein, beta polypeptide, neural |
decreases expression |
ISO |
Cycloheximide results in decreased expression of S100B mRNA |
CTD |
PMID:19146868 |
|
NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
multiple interactions |
ISO |
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]] |
CTD |
PMID:16637064 |
|
NCBI chr X:153,996,128...153,999,345
Ensembl chr X:153,996,128...153,999,445
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Sec11c |
SEC11 homolog C, signal peptidase complex subunit |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of SEC11C mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:65,933,649...65,950,731
Ensembl chr18:65,933,586...65,950,755
|
|
G |
Serpinb9 |
serine (or cysteine) peptidase inhibitor, clade B, member 9 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [moxestrol results in increased expression of SERPINB9 mRNA] |
CTD |
PMID:10681578 |
|
NCBI chr13:33,181,044...33,201,938
Ensembl chr13:33,187,233...33,201,940
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions |
EXP ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:9798919 PMID:11007951 PMID:12111005 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Serpine2 |
serine (or cysteine) peptidase inhibitor, clade E, member 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SERPINE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERPINE2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:79,772,038...79,836,382
Ensembl chr 1:79,771,914...79,838,897
|
|
G |
Sertad2 |
SERTA domain containing 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SERTAD2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERTAD2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:20,493,166...20,603,023
Ensembl chr11:20,493,253...20,603,021
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of SESN2 protein] |
CTD |
PMID:25637945 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of SGK1 protein] |
CTD |
PMID:25128767 |
|
NCBI chr10:21,758,083...21,875,802
Ensembl chr10:21,758,083...21,875,802
|
|
G |
Sirpa |
signal-regulatory protein alpha |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SIRPA mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:129,432,962...129,474,148
Ensembl chr 2:129,434,755...129,474,148
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide promotes the reaction [antimony trichloride results in decreased expression of SIRT1 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein] |
CTD |
PMID:30055241 PMID:31082419 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Sla |
src-like adaptor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLA mRNA] |
CTD |
PMID:9020066 |
|
NCBI chr15:66,652,713...66,703,921
Ensembl chr15:66,652,668...66,703,678
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC16A1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Slc1a1 |
solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLC1A1 mRNA] |
CTD |
PMID:19450544 |
|
NCBI chr19:28,812,535...28,891,360
Ensembl chr19:28,812,449...28,891,360
|
|
G |
Slc22a4 |
solute carrier family 22 (organic cation transporter), member 4 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SLC22A4 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC22A4 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:53,873,941...53,920,866
Ensembl chr11:53,873,949...53,918,916
|
|
G |
Slc25a27 |
solute carrier family 25, member 27 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC25A27 mRNA |
CTD |
PMID:20385226 |
|
NCBI chr17:43,948,630...43,978,105
Ensembl chr17:43,952,782...43,978,105
|
|
G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC2A1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [4-hydroxyisoleucine results in increased localization of SLC2A4 protein] |
CTD |
PMID:22610671 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc2a5 |
solute carrier family 2 (facilitated glucose transporter), member 5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Fructose promotes the reaction [SLC2A5 protein results in increased uptake of Fructose]] |
CTD |
PMID:11123204 |
|
NCBI chr 4:150,203,801...150,228,625
Ensembl chr 4:150,203,740...150,228,626
|
|
G |
Slc39a4 |
solute carrier family 39 (zinc transporter), member 4 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Zinc deficiency results in increased expression of SLC39A4 mRNA]; Cycloheximide inhibits the reaction [Zinc results in decreased expression of SLC39A4 mRNA] |
CTD |
PMID:18020946 |
|
NCBI chr15:76,496,583...76,501,579
Ensembl chr15:76,496,583...76,501,584
|
|
G |
Slc3a2 |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC3A2 mRNA |
CTD |
PMID:26621329 |
|
NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733
|
|
G |
Slc5a5 |
solute carrier family 5 (sodium iodide symporter), member 5 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC5A5 mRNA |
CTD |
PMID:17164311 |
|
NCBI chr 8:71,335,529...71,345,429
Ensembl chr 8:71,335,533...71,345,401
|
|
G |
Slc7a5 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC7A5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433
|
|
G |
Smn1 |
survival motor neuron 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Paraquat results in increased expression of SMN1 mRNA alternative form] |
CTD |
PMID:17064354 |
|
NCBI chr13:100,259,713...100,274,206
Ensembl chr13:100,261,360...100,274,198
|
|
G |
Snhg15 |
small nucleolar RNA host gene 15 |
multiple interactions |
ISO |
Cycloheximide results in increased stability of and results in increased expression of SNHG15 mRNA |
CTD |
PMID:24036268 |
|
NCBI chr11:6,475,591...6,478,760
Ensembl chr11:6,475,295...6,478,841
|
|
G |
Snw1 |
SNW domain containing 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SNW1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr12:87,496,680...87,519,069
Ensembl chr12:87,495,845...87,519,044
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
multiple interactions increases expression |
ISO EXP |
[afimoxifene co-treated with Cycloheximide] results in increased expression of SOCS1 mRNA Cycloheximide results in increased expression of SOCS1 mRNA |
CTD |
PMID:16849584 PMID:23237828 |
|
NCBI chr16:10,601,672...10,603,400
Ensembl chr16:10,600,104...10,603,400
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions increases expression |
EXP |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS2 mRNA] Cycloheximide results in increased expression of SOCS2 mRNA |
CTD |
PMID:15371557 PMID:23237828 |
|
NCBI chr10:95,219,765...95,253,176
Ensembl chr10:95,221,224...95,253,042
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression multiple interactions |
EXP |
Cycloheximide results in increased expression of SOCS3 mRNA Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]; U 0126 inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA] |
CTD |
PMID:23237828 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Socs4 |
suppressor of cytokine signaling 4 |
increases expression |
EXP |
Cycloheximide results in increased expression of SOCS4 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr14:47,514,377...47,533,559
Ensembl chr14:47,514,388...47,533,559
|
|
G |
Socs5 |
suppressor of cytokine signaling 5 |
increases expression |
EXP |
Cycloheximide results in increased expression of SOCS5 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr17:87,414,707...87,445,153
Ensembl chr17:87,415,107...87,445,267
|
|
G |
Socs6 |
suppressor of cytokine signaling 6 |
increases expression |
EXP |
Cycloheximide results in increased expression of SOCS6 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr18:88,883,293...88,912,623
Ensembl chr18:88,683,348...88,945,605
|
|
G |
Socs7 |
suppressor of cytokine signaling 7 |
increases expression |
EXP |
Cycloheximide results in increased expression of SOCS7 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr11:97,253,044...97,289,368
Ensembl chr11:97,253,261...97,289,368
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions increases expression |
EXP ISO |
Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]; Cycloheximide inhibits the reaction [polysaccharide-K results in increased expression of SOD2] Cycloheximide promotes the reaction [Paclitaxel results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vincristine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased expression of SOD2 mRNA] |
CTD |
PMID:8037686 PMID:9852137 PMID:11154046 PMID:15330761 PMID:20495008 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sort1 |
sortilin 1 |
multiple interactions increases degradation |
ISO EXP |
SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]; Docosahexaenoic Acids inhibits the reaction [Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]] Cycloheximide results in increased degradation of SORT1 protein mutant form |
CTD |
PMID:22555848 PMID:24986865 PMID:25805502 |
|
NCBI chr 3:108,191,272...108,268,835
Ensembl chr 3:108,191,398...108,268,827
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:80,701,181...80,787,882
Ensembl chr17:80,701,180...80,787,882
|
|
G |
Sptan1 |
spectrin alpha, non-erythrocytic 1 |
multiple interactions |
EXP |
[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:18182247 |
|
NCBI chr 2:29,855,572...29,921,463
Ensembl chr 2:29,855,572...29,921,463
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
[sodium arsenite results in increased abundance of arsenite] inhibits the reaction [Cycloheximide results in decreased expression of SQSTM1 protein]; Cycloheximide promotes the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]] |
CTD |
PMID:31781319 PMID:34405320 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Src |
Rous sarcoma oncogene |
increases localization |
ISO |
Cycloheximide results in increased localization of SRC protein |
CTD |
PMID:10401681 |
|
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Srr |
serine racemase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [methyllycaconitine results in increased expression of SRR protein] |
CTD |
PMID:24012499 |
|
NCBI chr11:74,794,853...74,818,427
Ensembl chr11:74,797,185...74,816,774
|
|
G |
Ssbp1 |
single-stranded DNA binding protein 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SSBP1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SSBP1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:40,448,302...40,458,757
Ensembl chr 6:40,448,286...40,461,634
|
|
G |
St18 |
suppression of tumorigenicity 18 |
increases expression |
EXP |
Cycloheximide results in increased expression of ST18 mRNA |
CTD |
PMID:23236509 |
|
NCBI chr 1:6,557,455...6,931,164
Ensembl chr 1:6,557,455...6,931,164
|
|
G |
St8sia1 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ST8SIA1 mRNA Cycloheximide results in increased expression of ST8SIA1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:142,767,267...142,935,247
Ensembl chr 6:142,767,271...142,910,178
|
|
G |
Stk3 |
serine/threonine kinase 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STK3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr15:34,875,645...35,155,990
Ensembl chr15:34,875,642...35,179,067
|
|
G |
Stx2 |
syntaxin 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STX2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:129,061,621...129,085,664
Ensembl chr 5:129,061,621...129,085,638
|
|
G |
Sult2b1 |
sulfotransferase family, cytosolic, 2B, member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SULT2B1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:45,379,405...45,409,096
Ensembl chr 7:45,379,407...45,434,093
|
|
G |
Supt4a |
SPT4A, DSIF elongation factor subunit |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SUPT4H1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:87,628,377...87,634,449
Ensembl chr11:87,628,378...87,634,449
|
|
G |
Synpo |
synaptopodin |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SYNPO mRNA Cycloheximide results in increased expression of SYNPO mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:60,727,053...60,793,241
Ensembl chr18:60,727,045...60,793,214
|
|
G |
Tac1 |
tachykinin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein] |
CTD |
PMID:16696851 |
|
NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834
|
|
G |
Tacc1 |
transforming, acidic coiled-coil containing protein 1 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of TACC1 mRNA Cycloheximide results in increased expression of TACC1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 8:25,644,568...25,730,901
Ensembl chr 8:25,644,568...25,746,604
|
|
G |
Tardbp |
TAR DNA binding protein |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of TARDBP protein Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein] |
CTD |
PMID:24477737 |
|
NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476
|
|
G |
Tas2r105 |
taste receptor, type 2, member 105 |
multiple interactions |
EXP |
Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in decreased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]]; TAS2R105 protein affects the reaction [Cycloheximide results in decreased abundance of Cyclic AMP] |
CTD |
PMID:15087236 |
|
NCBI chr 6:131,663,524...131,664,426
Ensembl chr 6:131,663,495...131,664,458
|
|
G |
Tas2r114 |
taste receptor, type 2, member 114 |
multiple interactions |
ISO |
TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]; TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15087236 |
|
NCBI chr 6:131,666,097...131,667,026
Ensembl chr 6:131,666,097...131,667,026
|
|
G |
Tbx3 |
T-box 3 |
increases expression |
ISO |
cycloheximide co-treated with all-trans-retinoic acid increases expression of TBX3 mRNA in melanoma cells |
RGD |
PMID:22535523 |
RGD:151361117 |
NCBI chr 5:119,808,600...119,822,789
Ensembl chr 5:119,808,734...119,822,789
|
|
G |
Tfap2a |
transcription factor AP-2, alpha |
decreases stability multiple interactions |
ISO |
Cycloheximide results in decreased stability of TFAP2A protein LINC-ROR promotes the reaction [Cycloheximide results in decreased stability of TFAP2A protein] |
CTD |
PMID:36576707 |
|
NCBI chr13:40,867,278...40,891,715
Ensembl chr13:40,868,778...40,891,852
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of TFF1 mRNA; Cycloheximide inhibits the reaction [bisphenol A results in increased expression of TFF1 mRNA] Cycloheximide results in increased expression of TFF1 mRNA |
CTD |
PMID:15072547 PMID:20875696 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
ISO |
Cycloheximide results in increased expression of TGFA mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases activity |
ISO |
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] Cycloheximide results in decreased activity of TGFB1 protein |
CTD |
PMID:9145908 PMID:9790906 PMID:9798919 PMID:21303922 PMID:31652400 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor II |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tolfenamic acid results in decreased expression of TGFBR2 protein] |
CTD |
PMID:31381904 |
|
NCBI chr 9:115,916,763...116,004,431
Ensembl chr 9:115,913,361...116,004,428
|
|
G |
Thbd |
thrombomodulin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THBD mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Testosterone results in decreased expression of THBS1 mRNA] |
CTD |
PMID:16723184 |
|
NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614
|
|
G |
Thy1 |
thymus cell antigen 1, theta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THY1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:43,954,681...43,959,876
Ensembl chr 9:43,954,681...43,959,876
|
|
G |
Tia1 |
cytotoxic granule-associated RNA binding protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [sodium arsenite affects the localization of TIA1 protein]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] |
CTD |
PMID:19171178 PMID:22555848 |
|
NCBI chr 6:86,381,001...86,410,387
Ensembl chr 6:86,381,201...86,410,387
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17a |
multiple interactions decreases expression |
ISO EXP |
Cycloheximide results in decreased expression of and results in increased degradation of TIMM17A protein; YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein] Cycloheximide results in decreased expression of TIMM17A protein |
CTD |
PMID:24315374 |
|
NCBI chr 1:135,229,273...135,241,475
Ensembl chr 1:135,222,951...135,241,516
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
decreases response to substance |
ISO |
TIMP1 protein results in decreased susceptibility to Cycloheximide |
CTD |
PMID:15860571 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
multiple interactions increases expression |
EXP |
AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA] |
CTD |
PMID:12147270 |
|
NCBI chr 3:65,435,868...65,462,939
Ensembl chr 3:65,435,831...65,462,939
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] Cycloheximide results in decreased expression of TJP1 protein |
CTD |
PMID:16087364 |
|
NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529
|
|
G |
Tm7sf3 |
transmembrane 7 superfamily member 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TM7SF3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:146,503,774...146,536,103
Ensembl chr 6:146,503,850...146,544,322
|
|
G |
Tmem263 |
transmembrane protein 263 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of TMEM263 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TMEM263 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:84,938,491...84,953,611
Ensembl chr10:84,938,491...84,956,482
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance multiple interactions |
ISO EXP |
TNF protein results in increased susceptibility to Cycloheximide [TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; Cycloheximide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Cycloheximide promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] Cycloheximide inhibits the reaction [TNF protein results in decreased export of Potassium]; Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] [Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of TNF protein]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; Cycloheximide inhibits the reaction [Zinc deficiency promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:8037686 PMID:8071060 PMID:12185005 PMID:12812920 PMID:12925536 PMID:15701621 PMID:16077199 PMID:17337591 PMID:18182247 PMID:21146893 PMID:22121136 PMID:22241084 PMID:22258905 PMID:22319556 PMID:22555848 PMID:24068670 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip1 |
tumor necrosis factor, alpha-induced protein 1 (endothelial) |
multiple interactions |
EXP |
TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein] |
CTD |
PMID:37302538 |
|
NCBI chr11:78,413,676...78,427,122
Ensembl chr11:78,413,676...78,427,158
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
multiple interactions |
ISO |
[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:21146893 |
|
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
|
|
G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [docetaxel results in increased expression of TNFRSF10A protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein] |
CTD |
PMID:11212279 |
|
NCBI chr14:70,004,921...70,021,860
Ensembl chr14:70,004,921...70,021,860
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of TNFRSF11B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf22 |
tumor necrosis factor receptor superfamily, member 22 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNFRSF10B mRNA] |
CTD |
PMID:27484784 |
|
NCBI chr 7:143,188,540...143,203,412
Ensembl chr 7:143,188,543...143,203,398
|
|
G |
Tnfrsf8 |
tumor necrosis factor receptor superfamily, member 8 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNFRSF8 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:144,993,702...145,041,734
Ensembl chr 4:144,993,707...145,041,734
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
multiple interactions |
ISO |
[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide]; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF10 mRNA] |
CTD |
PMID:11007951 PMID:18222423 PMID:22343715 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF11 mRNA] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:11007951 PMID:17295206 PMID:18327666 PMID:18636177 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Tnnc1 |
troponin C, cardiac/slow skeletal |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNNC1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr14:30,930,274...30,933,671
Ensembl chr14:30,930,269...30,933,686
|
|
G |
Trp53 |
transformation related protein 53 |
increases response to substance multiple interactions decreases expression increases degradation |
ISO EXP |
TP53 mutant form results in increased susceptibility to Cycloheximide Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein]; Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein]; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of TRP53 protein] Cycloheximide results in decreased expression of TP53 protein |
CTD |
PMID:9790906 PMID:10760090 PMID:15016801 PMID:20943951 PMID:21875941 PMID:27993609 PMID:31645432 PMID:35821281 More...
|
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trp53i11 |
transformation related protein 53 inducible protein 11 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of TP53I11 mRNA] Cycloheximide results in decreased expression of TP53I11 mRNA |
CTD |
PMID:19333544 |
|
NCBI chr 2:93,017,694...93,032,102
Ensembl chr 2:93,017,893...93,032,104
|
|
G |
Trp63 |
transformation related protein 63 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [trichostatin A results in increased expression of TP63 protein alternative form] |
CTD |
PMID:20043870 |
|
NCBI chr16:25,502,513...25,710,842
Ensembl chr16:25,502,513...25,710,852
|
|
G |
Tubgcp3 |
tubulin, gamma complex component 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TUBGCP3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:12,664,277...12,722,141
Ensembl chr 8:12,664,277...12,722,248
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Acrolein results in increased expression of TXNRD1 mRNA]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA] |
CTD |
PMID:12663510 PMID:15652504 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Tymp |
thymidine phosphorylase |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of TYMP protein salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]] |
CTD |
PMID:30796972 |
|
NCBI chr15:89,255,834...89,261,282
Ensembl chr15:89,256,134...89,261,242
|
|
G |
Tyms |
thymidylate synthase |
multiple interactions decreases expression |
ISO |
cinobufagin promotes the reaction [Cycloheximide results in decreased expression of TYMS protein]; Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA] |
CTD |
PMID:17172411 PMID:35427566 |
|
NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Quercetin results in increased activity of TYR protein] [resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein; SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein] |
CTD |
PMID:14717847 PMID:29621941 |
|
NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720
|
|
G |
Uchl1 |
ubiquitin carboxy-terminal hydrolase L1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Mevinphos results in increased expression of UCHL1 protein] |
CTD |
PMID:15545831 |
|
NCBI chr 5:66,833,464...66,844,577
Ensembl chr 5:66,833,434...66,844,577
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of UGT1A1 mRNA Cycloheximide results in decreased expression of UGT1A1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719
|
|
G |
Ugt1a6b |
UDP glucuronosyltransferase 1 family, polypeptide A6B |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Paraquat results in increased expression of UGT1A6 mRNA] |
CTD |
PMID:22846377 |
|
NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725
|
|
G |
Ulk1 |
unc-51 like kinase 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of ULK1 protein Antimycin A inhibits the reaction [Cycloheximide results in decreased expression of ULK1 protein]; Cycloheximide inhibits the reaction [Antimycin A results in increased expression of ULK1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 5:110,932,355...110,957,991
Ensembl chr 5:110,932,354...110,957,963
|
|
G |
Usp7 |
ubiquitin specific peptidase 7 |
multiple interactions |
ISO |
USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein] |
CTD |
PMID:35821281 |
|
NCBI chr16:8,506,586...8,574,931
Ensembl chr16:8,507,459...8,610,172
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
EXP |
VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:18182247 |
|
NCBI chr 7:18,990,854...19,005,779
Ensembl chr 7:18,990,854...19,005,742
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] |
CTD |
PMID:12892526 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO EXP |
Cycloheximide promotes the reaction [Estradiol results in increased expression of VEGFA mRNA alternative form] [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA Cycloheximide results in increased expression of VEGFA mRNA Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA] |
CTD |
PMID:8344219 PMID:8537383 PMID:10788502 PMID:11641398 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vegfd |
vascular endothelial growth factor D |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VEGFD mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646
|
|
G |
Virma |
vir like m6A methyltransferase associated |
affects response to substance |
ISO |
VIRMA gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 4:11,485,958...11,551,143
Ensembl chr 4:11,485,958...11,550,684
|
|
G |
Vldlr |
very low density lipoprotein receptor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VLDLR mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr19:27,190,070...27,231,631
Ensembl chr19:27,193,884...27,231,631
|
|
G |
Vsnl1 |
visinin-like 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VSNL1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:11,375,258...11,486,579
Ensembl chr12:11,375,243...11,486,614
|
|
G |
Wwox |
WW domain-containing oxidoreductase |
affects response to substance |
ISO |
WWOX gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 8:115,166,377...116,079,451
Ensembl chr 8:115,166,395...116,079,447
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Yap1 |
yes-associated protein 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of YAP1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:7,932,000...8,004,890
Ensembl chr 9:7,932,000...8,004,597
|
|
G |
Yme1l1 |
YME1-like 1 (S. cerevisiae) |
multiple interactions |
ISO |
YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein] |
CTD |
PMID:24315374 |
|
NCBI chr 2:23,046,517...23,089,272
Ensembl chr 2:23,046,381...23,089,272
|
|